Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $17.67 Average PT from Brokerages
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month price target […]
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month price target […]
